Nathan Avaritt

Researcher

University of Arkansas for Medical Sciences

faculty

7 h-index 43 pubs 204 cited

Research Areas

Cancer-related molecular mechanisms research Cancer Immunotherapy and Biomarkers Cancer Treatment and Pharmacology Gut microbiota and health Molecular Biology Techniques and Applications Metabolomics and Mass Spectrometry Studies Microbial infections and disease research

Links

ORCID Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Nathan Avaritt investigates molecular mechanisms underlying melanoma, with a focus on understanding how specific genetic and cellular processes influence cancer progression and response to therapy. His recent publications explore the role of EZH2 loss in restoring MHC class I expression in melanoma, the potential of ATF4 activation to enhance responses to immune checkpoint blockade, and the synthesis of novel compounds with anti-melanoma activity. Additionally, Avaritt has published on the anti-melanoma effects of fungal mycelium and the use of CRISPR/dCas9-KRAB to suppress S100b, a strategy aimed at restoring p53-mediated apoptosis in melanoma cells. His work also extends to the gut microbiome, with research examining how C-section influences specific bacterial populations in mice, and to the protective effects of factor XI inhibition in a baboon model of sepsis. Avaritt collaborates extensively with researchers at the University of Arkansas for Medical Sciences, including Alan J. Tackett, Billie Heflin, Brian Koss, and Sanjay Adhikary.

Metrics

h-index: 7
Publications: 43
Citations: 204

Selected Publications

691 ATF6 activation promotes ICB response in melanoma (2025) DOI
Anthrax toxins exacerbate sepsis-induced coagulopathy and endothelial dysfunction in a baboon model of anthrax (2025) DOI
Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis (2025) DOI
EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma (2025) DOI
Abstract 4622: Proteomic insights into anti-CTLA4 therapy resistance in metastatic melanoma: Pathway-specific biomarkers for treatment response (2025) DOI
Correction: Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors (2025) DOI
Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors (2024) DOI
538 ATF6 activation in melanoma promotes anti-tumor immunity and improves ICB therapy response (2024) DOI
Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues (2023) DOI
Supplementary Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy (2023) DOI
Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy (2023) DOI
Supplementary Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy (2023) DOI
Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy (2023) DOI
Cutting-Edge Technologies Driving Quantitative Mass Spectrometry (2023) DOI
Cutting-Edge Technologies Driving Quantitative Mass Spectrometry (2023) DOI